Navigation Links
NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference
Date:5/18/2009

Data demonstrates that NewCardio's platform technology delivers new levels of analysis of heart's electrical activity

SANTA CLARA, Calif., May 18 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced that members of the Company's medical and technology teams presented two abstracts and discussed new clinical data from analytical and clinical applications of its proprietary platform technology at The Heart Rhythm Society (HRS) 30th Annual Scientific Sessions on May 13-16, 2009 in Boston, MA.

NewCardio introduced the NewCardio platform, QTinno(TM) and Visual3Dx(TM), at Heart Rhythm 2009 30th Annual Scientific Sessions. The Company believes that its QTinno(TM), software-based, analytical technology is the industry's first solution for the reliable automated analysis of ECGs used to determine cardiac toxicity during drug development. Visual3Dx(TM) will generate 3D information from the heart using standard 12-lead ECG data. It is expected to provide clinicians additional information on the extent and localization of acute ischemic insult to the heart to improve the speed and accuracy of diagnosis of Acute Coronary Syndrome.

HRS is the international leader in science, education and advocacy for cardiac arrhythmia professionals and patients, and the primary information resource on heart rhythm disorders. Its mission is to improve the care of patients by promoting research, education and optimal health care policies and standards. The Annual Scientific Sessions attract more than 9,000 professionals representing the allied specialties of cardiac pacing and cardiac electrophysiology. More information is available at http://www.hrsonline.org/Sessions/ on the Internet.

The two abstracts prese
'/>"/>

SOURCE NewCardio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. NewCardio Announces New Client Services Team
2. NewCardio Restructures 2007 Financing, Receives $2.8 Million Additional Cash and Improves Capital Structure
3. NewCardio to Present at OneMedForum 2009: Disrupters and Drivers on January 13 in San Francisco
4. NewCardio Leadership to Present Clinical Data of Fully Automated QTinno(TM) Study at American College of Cardiology Annual Meeting
5. UPDATE: NewCardio Leadership to Present Clinical Data of Fully Automated QTinno(TM) Study at American College of Cardiology Annual Meeting
6. NewCardio Elects Michael E. Hanson to Board of Directors
7. NewCardio Leadership to Make Two Presentations at Drug Information Association Drug Safety Conference
8. NewCardio to Introduce Technology at Heart Rhythm Society Conference
9. MSU engineering team designs innovative medical device
10. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
11. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...les may reduce future disease burden, researchers ... -- Encouraging city dwellers to walk and bicycle ...lic health benefits than increased used of low-emi...The study compared the projected health effects in...s for London, England, and Delhi, India: business...
(Date:11/27/2009)...ingual coloring books designed for children ages 2... to educate - inform parents and children alike on...uars to ABC,S and a host of other topics. , ...r 27, 2009 -- Today’s children have enough g...hour of the day, but one of the oldest and simples...
(Date:11/26/2009)...ewswire/ -- The diabetes population in the United ...nd annual medical spending on the disease is proje...ay, according to a study published in the December... Diabetes ® Program (NCDP), a program of Novo... the University of Chicago. ,, According to the...
(Date:11/26/2009)...al rollercoaster, study finds , , THURSD...actor meets the jubilant sports fan. , A new st...ho root for the winning team -- enjoy the greatest...d victory was in doubt, producing feelings of worr...iving weekend as you,re glued to the TV set, watch...
(Date:11/26/2009)...ions announces a highly effective and unconvention... to make an economic recovery. , ...the type of challenge that could send ailing holid...avid Benton, business growth expert and author of ... The Rfactor Intensive . “Fear is one of t...
Breaking Medicine News(10 mins):Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Pharmacist Injects Cure for Ailing Businesses 2
...s by American scientists has revealed a startling ...opean descent have DNA that is linked to// the ris...ll. These genes lie close to another set that is... if they do not have clear risk factors such as sm...
...can doctor has threatened to mobilise US congressm... him information// under the Right to Information ...t the corrupt healthcare system here. Kunal...sk them to raise this issue with the Indian govern...
...an Resource Development in collaboration with Nati... an educational programme,// known as Adolescence ...ed by all the States and Union Territories of the ...ng up during adolescence, HIV/AIDS and drug (subst...
...tudents here have developed a device that can enab.../. Called 'E-Netra', it costs Rs.2,000-3,000 ...converts them into voice that can be heard through...six months to develop the device and the software ...
...c technology to detect epidemic diseases has enter...inese scientist//. Different from traditiona...he new technology is based on genetic substances o... of US National Institutes of Health (NIH). ...
... women who consumed higher levels of calcium and v...ater volumes of brain lesions, regions of damage//...ementia, depression and stroke. Dr. Payne a... 153 women) between the ages of 60 and 86 (average...
Other Medicine News:Health News:Gene Mutations Leave Caucasians Prone To Heart Diseases And Diabetes 2Health News:NRI Threatens to Move US Congress for Justice in India 2Health News:Higher Intake of Calcium and Vitamin D Linked With Brain Lesions in Older People 2
(Date:11/25/2009)...wire-FirstCall/ -- ERT (Nasdaq: ERES ), announced... President and CEO, and Keith Schneck, the Company... to present at the 21st Annual Piper Jaffray Healt...09 in New York City, New York. ,, Interested pa...Company,s corporate website at http://www.ert.com...
(Date:11/25/2009)...ire/ -- The FDA granted traditional approval for I...ide reverse transcriptase inhibitor (NNRTI). INTEL...use in treatment-experienced adults who are experi...ant to an NNRTI and other antiretroviral (ARV) age... data from two Phase 3 studies known as DUET-1 and...
(Date:11/25/2009)...RNewswire/ -- AMPAC Fine Chemicals LLC (AFC), a su... APFC ) announced today that it received the Envir...t the Annual Statewide Environmental Summit, spons...y Association (CMTA), the Industrial Environmental...il of California (CICC) held in San Diego. This i...
Breaking Medicine Technology:ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 5AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 3Stem Cells Grow Heart Tissue in Lab 59556 1Stem Cells Grow Heart Tissue in Lab 59556 2Stem Cells Grow Heart Tissue in Lab 59556 3Medical Transcription Services Provider MxSecure Names Healthcare IT Expert Mark McLaughlin New Chief Technology Officer 59553 1Medical Transcription Services Provider MxSecure Names Healthcare IT Expert Mark McLaughlin New Chief Technology Officer 59553 2Medical Transcription Services Provider MxSecure Names Healthcare IT Expert Mark McLaughlin New Chief Technology Officer 59553 3Astrup Drug Implements ECRS Retail Solution Suite to Address Diverse Business Requirements 59550 1Astrup Drug Implements ECRS Retail Solution Suite to Address Diverse Business Requirements 59550 2
...inary Phase II Results Encouraging and Support Pha...ternational,Inc. (NYSE: BAX ) and The Alzheimer,s...unced the decision to pursue a multi-center U.S. P...quid [Immune Globulin Intravenous,(Human)] (IGIV),...e,treatment of patients with mild to moderate alzh...
...rack to have Phase 3 data available by the spring ...tion applications expected by the ...28 Human Genome,Sciences, Inc. (Nasdaq: HGSI ) t...d initial dosing ahead of schedule in ACHIEVE 1, t...n(R) (albinterferon alfa-2b) in,combination with r...
Other Medicine Technology:Baxter and The Alzheimer's Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimer's Disease 2Baxter and The Alzheimer's Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimer's Disease 3Baxter and The Alzheimer's Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimer's Disease 4Baxter and The Alzheimer's Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimer's Disease 5Baxter and The Alzheimer's Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimer's Disease 6Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule 2Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule 3Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule 4Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule 5
CX41 Microscopes
CX31 Microscopes
...designed from the ground-up with ergonomic concern...justable observation tube on the market. Optional ...every user can adjust the microscope to suit their...s the operator maintain an upright, comfortable po...
Eclipse TS100F
Medicine Products: